Metis TechBio Co., Ltd. released its unaudited interim results for the six months ended 30 June 2026, highlighting a sharp revenue inflection driven by external licensing agreements and ongoing platform monetisation.
Financial Performance 1. Revenue jumped to RMB154.29 million, a 13,399% increase from RMB1.14 million in 1H25, fuelled mainly by collaboration income of RMB153.61 million. 2. R&D expenditure rose 48.10% year-on-year to RMB172.37 million as the company advanced multiple therapeutic programmes and AI-driven platforms. 3. Net loss attributable to shareholders narrowed 20.0% to RMB153.21 million, while non-IFRS adjusted net loss was cut by 56.40% to RMB51.10 million. 4. Cash, term deposits and financial assets at fair value totalled RMB3.03 billion at period-end, underpinned by RMB2.12 billion of IPO proceeds in May 2026. 5. Gearing ratio improved to 8.9% from 19.3% at end-2025; no interim dividend was declared.
Operational Highlights • Key AI Platforms: Continued enhancement of AiLNP (lipid nanoparticle design), AiProtein (antibody generation and engineering), AiRNA (mRNA optimisation) and AiTEM (small-molecule formulation). • Pipeline Progress: – MTS-004 advancing toward NDA filing following completion of validation production. – MTS-201 completed Phase I Part B; Part C underway. – MTS-105 and MTS-109 progressing in investigator-initiated trials; dual China/U.S. INDs for MTS-109 in preparation. – Multiple discovery and pre-clinical assets (e.g., MTS-107, MTS-108, MTS-110) moved toward CMC or PCC milestones. • Targeted Delivery Breakthroughs: Achieved high-throughput DNA-barcoded LNP screening in non-human primates, developed cardiomyocyte-targeted LNPs with >95% transfection efficiency, and advanced a “plug-and-play” in vivo CAR-T LNP platform.
Commercial & Partnership Developments • Granted Boulevard Bio a global exclusive licence for trispecific TCE MTS-128, receiving an upfront US$20 million and eligible for up to US$1.60 billion in milestones plus tiered royalties. • Licensed LNP technology to BioThunder AG for up to 10 in vivo CAR-T products, securing RMB15 million upfront. • OpenCGT partnership network expanded; cumulative potential transaction value now exceeds RMB6 billion with new collaborations targeting liver and lung delivery systems. • Post-period agreements include local deployment of the AiTEM formulation platform with Hengrui Pharma and a strategic “AI+CDMO” alliance with Apeloa Pharmaceutical.
Liquidity & Cash Flow Operating cash outflow was RMB162.20 million, reflecting heightened R&D and commercial activities. Net financing inflow of RMB2.09 billion, primarily from the Hong Kong IPO, lifted cash and equivalents to RMB2.53 billion.
Outlook Management reiterates its strategy to leverage AI4S and Biological AI to progress from molecular design to cell reprogramming, aiming to meet the Hong Kong Listing Rule revenue threshold in 2027.